Based on the significant efficacy and acceptable toxicity profile, this combination therapy was approved by the FDA for treatment naïve metastatic ccRCC, irrespective of PDL1 status or IMDC risk stratification. Here, CD274 is linked to nonpapillary renal cell carcinoma.